Burwinkel B, Kreuder J, Schweitzer S, Vorgerd M, Gempel K, Gerbitz KD, Kilimann MW: Carnitine transporter OCTN2 mutations in systemic primary carnitine deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter mutation associated with an unconventional splicing abnormality
Adherence concerns: Many people stop treatment early, leading insurers to question the long-term return on investment for these medications
You likely already know what semaglutide is and how it works, if you're here reading our posts
Ozempic , which contains the active ingredient semaglutide GLP-1 , is a medication designed to mimic the effects of GLP-1 in the body
If you believe you are experiencing side effects from Rybelsus, you can report them through the MHRA Yellow Card Scheme, which helps monitor the safety of medicines